NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous ...

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced ...

The Brain Prize 2025 went to neuro-oncologists Michelle Monje and Frank Winkler for pioneering the field of cancer n.

Limited’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade ...

Circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) of patients with glioma had a high concordance with tumor DNA and ...

The development of ocular signs of neurofibromatosis type 1 (NF1) is only significant in patients 7 years of age and younger.

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company developing targeted immunotherapies, reported a reduced net los ...

本项研究认为，基于观察结果，在高级别胶质瘤手术中使用5-ALA能够增加肿瘤的切除范围，并 改善患者的预后。此外，与复发性肿瘤相比，5-ALA在原发性肿瘤中的使用效果更好（对于原发性胶质瘤，p<0.0001）。

NeOnc Technologies (NTHI) announced that the U.S. Food and Drug Administration, FDA, has granted Rare Pediatric Disease Designation, RPDD, to ...

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) shares slid as the Westlake Village, Calif.-based company a clinical-stage medical biotechnology concerm, announced that the U.S. Food and Drug ...

NeOnc Technologies Holdings, Inc. (NASDAQ Global Market: NTHI), a clinical-stage medical biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare ...